Genetic Signatures Ltd
ASX:GSS

Watchlist Manager
Genetic Signatures Ltd Logo
Genetic Signatures Ltd
ASX:GSS
Watchlist
Price: 0.345 AUD -4.17% Market Closed
Market Cap: 78.4m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GSS stock under the Base Case scenario is 0.711 AUD. Compared to the current market price of 0.345 AUD, Genetic Signatures Ltd is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSS Relative Value
Base Case
0.711 AUD
Undervaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
77
vs Industry
29
Median 3Y
5.1
Median 5Y
6.2
Industry
4
Forward
4.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-4.9
Industry
31.5
Forward
-3.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-11.1
Industry
19.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-9.7
Industry
32.5
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
98
vs Industry
47
Median 3Y
2.4
Median 5Y
2.7
Industry
2.7
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
95
vs Industry
41
Median 3Y
3.8
Median 5Y
4.9
Industry
3.8
Forward
2.1
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
93
vs Industry
43
Median 3Y
7.3
Median 5Y
8.9
Industry
8.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.2
Industry
17.6
Forward
-1.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.2
Industry
23.9
Forward
-1.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8.1
Industry
18.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-7.3
Industry
23.3
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
88
vs Industry
20
Median 3Y
4.2
Median 5Y
5
Industry
2.4
More Details

Multiples Across Competitors

GSS Competitors Multiples
Genetic Signatures Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Genetic Signatures Ltd
ASX:GSS
78.4m AUD 4.3 -3.5 -2.4 -2.4
US
PerkinElmer Inc
LSE:0KHE
1.1T USD 413.2 3 992.8 1 399.8 2 855.1
US
Thermo Fisher Scientific Inc
NYSE:TMO
180.6B USD 4.2 27.7 19 26.3
US
Danaher Corp
NYSE:DHR
147.1B USD 6.1 43.1 22.5 33.9
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW 14.5 55.6 32.3 44.9
CH
Lonza Group AG
SIX:LONN
39.6B CHF 6 62.3 22.8 35.6
US
IQVIA Holdings Inc
NYSE:IQV
34.7B USD 2.2 26 13.6 20.2
US
Agilent Technologies Inc
NYSE:A
34.1B USD 5.1 29.3 19.8 23.4
CN
WuXi AppTec Co Ltd
SSE:603259
256.7B CNY 6.3 23 22.4 22.4
US
Mettler-Toledo International Inc
NYSE:MTD
26.3B USD 6.9 30.9 22.9 25.4
IN
Divi's Laboratories Ltd
NSE:DIVISLAB
1.8T INR 19.1 79.5 57.7 66.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Genetic Signatures Ltd
ASX:GSS
Average EV/EBITDA: 163.3
Negative Multiple: -2.4 		N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 399.8
7%
200
US
Thermo Fisher Scientific Inc
NYSE:TMO
19
6%
3.2
US
Danaher Corp
NYSE:DHR
22.5
7%
3.2
KR
Samsung Biologics Co Ltd
KRX:207940
32.3
17%
1.9
CH
Lonza Group AG
SIX:LONN
22.8
18%
1.3
US
IQVIA Holdings Inc
NYSE:IQV
13.6
9%
1.5
US
Agilent Technologies Inc
NYSE:A
19.8
10%
2
CN
WuXi AppTec Co Ltd
SSE:603259
22.4
24%
0.9
US
Mettler-Toledo International Inc
NYSE:MTD
22.9
4%
5.7
IN
Divi's Laboratories Ltd
NSE:DIVISLAB
57.7
24%
2.4

See Also

Summary
GSS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GSS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GSS stock valuation using valuation multiples.
Wall Street Estimates
GSS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GSS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.